Apellis recalls 61K injection needles
Apellis Pharmaceuticals, a biotech drug company, has recalled more than 61,000 injection needle kits after eight retinal vasculitis cases were reported.
Source: beckershospitalreview.com
Retinal Vasculitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Retinal Vasculitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Retinal Vasculitis Today - Breaking & Trending Today
Apellis Reviewing Retinal Vasculitis Cases in Pegcetacoplan-Treated GA Patients
Reports of a half-dozen confirmed cases of the rare vision-threatening condition has spurred conversation around the first-in-class geographic atrophy drug.
Source: hcplive.com
Significant Decreases in Ocular Blood Flow Observed with Brolucizumab, Aflibercept Injections
Intravitreal brolucizumab and aflibercept in eyes with nAMD were each linked to a significant decrease in the ocular blood flow 30 minutes after injection.
Source: hcplive.com
Business.Scoop » Retinal Biologics Market Is Anticipated To Grow Significantly To Reach US$ 41.92 Billion By 2028 – FMI Research Report
Business Scoop provides news and views on Business and Markets from New Zealand
Source: scoop.co.nz
Canine Arthritis Treatment Market is predicted to rise at a CAGR of 4.2% and attain a market valuation of US$ 3.05 Bn by 2028 – Future Market Insights
DUBAI, United Arab Emirates, The global Canine Arthritis Treatment Market stands at a net worth of US$ 2.39 Bn in 2022.
Source: biospace.com